Scarica l'app Stockscreener
2.60
0.39%
0.01
Precedente Chiudi:
$2.59
Aprire:
$2.62
Volume 24 ore:
24,556
Relative Volume:
0.23
Capitalizzazione di mercato:
$2.40M
Reddito:
-
Utile/perdita netta:
$-15.52M
Rapporto P/E:
-0.1399
EPS:
-18.58
Flusso di cassa netto:
$-16.61M
1 W Prestazione:
-14.75%
1M Prestazione:
-8.93%
6M Prestazione:
-78.48%
1 anno Prestazione:
-91.49%
Intervallo 1D:
$2.5001
$2.68
Intervallo di 1 settimana:
$2.44
$3.27
Portata 52W:
$2.36
$60.80
Revelation Biosciences Inc Stock (REVB) Company Profile
Nome
Revelation Biosciences Inc
Settore
Industria
Telefono
650-800-3717
Indirizzo
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Confronta REVB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
2.5001 | 2.92M | 0 | -15.52M | -16.61M | -18.58 |
|
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.86 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.49 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.85 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Revelation Biosciences Inc Borsa (REVB) Ultime notizie
REVB: New Market Potential and Quarterly Results - Research Tree
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 - BioSpace
Revelation Biosciences (REVB) Projected to Post Earnings on Friday - Defense World
Allergic Rhinitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, - openPR.com
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - BioSpace
REVB: New Target Market Announced - Research Tree
Major Breakthrough: Revelation Bio and Vanderbilt Target Severe Burn Infections with Gemini Platform - Stock Titan
Peripheral Blood Mononuclear Cells Market Size to Hit USD 774.41 Bn by 2034 - Precedence Research
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics - GlobeNewswire
REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com
REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks
Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa
Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com
Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com
Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
Artificial Intelligence (AI) News Live Feed - StockTitan
Revelation Biosciences gets continued listing approval from Nasdaq - MSN
Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire
Larchmont broker accused of years-long insider trading scheme - Westfair Communications
Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR
Revelation Biosciences stock hits 52-week low at $0.28 - MSN
REVB Start 1B Trial and Announces Split - MSN
REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Anthem man charged with insider trading - The Foothills Focus
Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace
Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN
Revelation Biosciences Inc Azioni (REVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):